Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

SOHO 2020 | Next questions for mantle cell lymphoma

Jonathon Cohen • 9 Sep 2020
SOHO 2020
Lymphoma Mantle Cell Lymphoma CAR-T

Jonathon B. Cohen, MD, MS, of Winship Cancer Institute of Emory University, Atlanta, GA, outlines the next questions in mantle cell lymphoma, including a greater understanding of the requirement of frontline therapies, the management of disease using minimal residual measurements, as well as identifying patients appropriate for CAR T-cell therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jonathon Cohen

Immunotherapeutic approaches for MCL patients who progress following BTKi treatment
0:57
Immunotherapeutic approaches for MCL patients who progress following BTKi treatment
Jonathon Cohen • 11 Dec 2023
Outcomes of patients with MCL who require urgent treatment at time of diagnosis
0:49
Outcomes of patients with MCL who require urgent treatment at time of diagnosis
Jonathon Cohen • 11 Dec 2023
A pooled analysis to determine the optimal Ki-67 index cut-off point for predicting outcomes in MCL
0:55
A pooled analysis to determine the optimal Ki-67 index cut-off point for predicting outcomes in MCL
Jonathon Cohen • 11 Dec 2023
Updated results of the BRUIN trial: pirtobrutinib in R/R MCL
0:55
Updated results of the BRUIN trial: pirtobrutinib in R/R MCL
Jonathon Cohen • 11 Dec 2023

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Jonathon Cohen • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Jonathon Cohen • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Jonathon Cohen • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Jonathon Cohen • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals